Aardvark Therapeutics (NASDAQ:AARD) Earns Outperform Rating from Analysts at Royal Bank of Canada

Stock analysts at Royal Bank of Canada started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research report issued on Monday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $21.00 price target on the stock. Royal Bank of Canada’s price objective would indicate a potential upside of 107.31% from the stock’s current price.

Separately, Cantor Fitzgerald assumed coverage on Aardvark Therapeutics in a research report on Monday. They set an “overweight” rating and a $50.00 price target on the stock.

Aardvark Therapeutics Price Performance

Shares of Aardvark Therapeutics stock opened at $10.13 on Monday. Aardvark Therapeutics has a 12-month low of $9.21 and a 12-month high of $19.58.

Insider Buying and Selling at Aardvark Therapeutics

In other news, CEO Tien-Li Lee bought 16,542 shares of the stock in a transaction on Friday, February 14th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the purchase, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at $23,938,800. This trade represents a 1.12 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Nelson Sun bought 10,000 shares of the stock in a transaction on Friday, February 14th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $160,000.00. Following the purchase, the chief financial officer now directly owns 99,484 shares of the company’s stock, valued at approximately $1,591,744. This represents a 11.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.